Compare OIS & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OIS | DRUG |
|---|---|---|
| Founded | 1995 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 406.3M | 707.1M |
| IPO Year | 2000 | 2020 |
| Metric | OIS | DRUG |
|---|---|---|
| Price | $11.92 | $73.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $14.00 | ★ $124.00 |
| AVG Volume (30 Days) | ★ 1.5M | 82.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,088,133,000.00 | N/A |
| Revenue This Year | $3.73 | N/A |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 62.26 | N/A |
| 52 Week Low | $3.08 | $23.18 |
| 52 Week High | $14.50 | $123.75 |
| Indicator | OIS | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 54.81 | 39.82 |
| Support Level | $5.72 | $72.06 |
| Resistance Level | $14.50 | $91.00 |
| Average True Range (ATR) | 0.61 | 4.43 |
| MACD | -0.24 | -1.16 |
| Stochastic Oscillator | 12.53 | 18.84 |
Oil States International Inc is a provider of manufactured products and services to the energy, industrial and military sectors. Manufactured products include engineered capital equipment as well as products consumed in the drilling, well construction and production of oil and natural gas. The company sells its products and services to national oil and natural gas companies, oil and natural gas companies, onshore and offshore drilling companies and other oilfield services, defense and industrial companies. The company operates through three business segments, Offshore Manufactured Products, Completion and Production Services and Downhole Technologies. It gains maximum revenue from Offshore Manufactured Products.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.